Immix Biopharma (IMMX) Net Income towards Common Stockholders (2021 - 2026)

Immix Biopharma has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$10.1 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$10.1 million, down 122.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.0 million (down 4300.29% YoY), and the FY2025 annual result was -$29.4 million, down 1759.03% from the prior year.
• Net Income towards Common Stockholders came in at -$10.1 million for Q1 2026 at Immix Biopharma, up from -$10.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $15.3 million in Q4 2024 to a low of -$10.7 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$4.4 million (2024), against an average of -$3.8 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 649.04% in 2022 and jumped 396.83% in 2024, its largest moves.
• Immix Biopharma's Net Income towards Common Stockholders stood at -$3.8 million in 2022, then slumped by 35.67% to -$5.2 million in 2023, then surged by 396.83% to $15.3 million in 2024, then slumped by 169.84% to -$10.7 million in 2025, then increased by 5.62% to -$10.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$10.1 million (Q1 2026), -$10.7 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.